ECSP055726A - Composición farmacéutica estabilizada que contiene excipientes básicos - Google Patents
Composición farmacéutica estabilizada que contiene excipientes básicosInfo
- Publication number
- ECSP055726A ECSP055726A EC2005005726A ECSP055726A ECSP055726A EC SP055726 A ECSP055726 A EC SP055726A EC 2005005726 A EC2005005726 A EC 2005005726A EC SP055726 A ECSP055726 A EC SP055726A EC SP055726 A ECSP055726 A EC SP055726A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- composition containing
- stabilized pharmaceutical
- containing basic
- basic excipients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención proporciona una composición farmacéutica estabilizada en una forma de dosificación oral que comprende un compuesto de la fórmula donde: R11, R10, R5, R6, R7, R8, R, Y, X, k, p, y n son como aquí se definen, o sus sales farmacéuticamente aceptables, ésteres o éteres del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41780402P | 2002-10-11 | 2002-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055726A true ECSP055726A (es) | 2005-07-06 |
Family
ID=32094094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005726A ECSP055726A (es) | 2002-10-11 | 2005-04-11 | Composición farmacéutica estabilizada que contiene excipientes básicos |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040122048A1 (es) |
EP (1) | EP1549297A2 (es) |
JP (1) | JP2006504734A (es) |
KR (1) | KR20050049541A (es) |
CN (1) | CN1703204A (es) |
AR (1) | AR041585A1 (es) |
AU (1) | AU2003279803A1 (es) |
BR (1) | BR0314612A (es) |
CA (1) | CA2500375A1 (es) |
EC (1) | ECSP055726A (es) |
MX (1) | MXPA05003671A (es) |
NO (1) | NO20051389L (es) |
NZ (1) | NZ539254A (es) |
RU (1) | RU2005113988A (es) |
TW (1) | TW200410692A (es) |
WO (1) | WO2004032909A2 (es) |
ZA (1) | ZA200502842B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
US20060068009A1 (en) * | 2004-09-30 | 2006-03-30 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
ES2733348T3 (es) * | 2007-08-17 | 2019-11-28 | Boehringer Ingelheim Int | Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP |
AR071175A1 (es) * | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20110044780A (ko) | 2008-08-14 | 2011-04-29 | 교린 세이야꾸 가부시키 가이샤 | 안정화된 의약 조성물 |
CA2735562C (en) * | 2008-08-15 | 2017-10-17 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for wound healing |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
EA030999B1 (ru) * | 2009-10-02 | 2018-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Применение фармацевтической композиции, включающей ингибитор дпп-4 и гидрохлорид метформина |
CA2780332C (en) * | 2009-11-09 | 2018-01-30 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
JP6168673B2 (ja) * | 2015-10-07 | 2017-07-26 | 協和発酵キリン株式会社 | アリールアルキルアミン化合物含有医薬組成物 |
TWI740873B (zh) | 2015-12-24 | 2021-10-01 | 日商協和麒麟股份有限公司 | α、β不飽和醯胺化合物 |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
EP3712129A4 (en) * | 2017-06-23 | 2020-12-09 | Kyowa Kirin Co., Ltd. | ALPHA AMIDE COMPOUND, BETA-UNSATURATED |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282790A (en) * | 1963-05-31 | 1966-11-01 | Upjohn Co | Enteric coated tablet |
US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
MXPA04005647A (es) * | 2002-02-01 | 2005-03-23 | Pfizer Prod Inc | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo. |
-
2003
- 2003-09-30 US US10/675,161 patent/US20040122048A1/en not_active Abandoned
- 2003-10-02 TW TW092127662A patent/TW200410692A/zh unknown
- 2003-10-03 EP EP03773132A patent/EP1549297A2/en not_active Withdrawn
- 2003-10-03 AU AU2003279803A patent/AU2003279803A1/en not_active Abandoned
- 2003-10-03 BR BR0314612-0A patent/BR0314612A/pt not_active IP Right Cessation
- 2003-10-03 MX MXPA05003671A patent/MXPA05003671A/es not_active Application Discontinuation
- 2003-10-03 RU RU2005113988/15A patent/RU2005113988A/ru not_active Application Discontinuation
- 2003-10-03 CN CNA2003801012951A patent/CN1703204A/zh active Pending
- 2003-10-03 KR KR1020057006279A patent/KR20050049541A/ko not_active Application Discontinuation
- 2003-10-03 CA CA002500375A patent/CA2500375A1/en not_active Abandoned
- 2003-10-03 WO PCT/US2003/031448 patent/WO2004032909A2/en active Application Filing
- 2003-10-03 NZ NZ539254A patent/NZ539254A/xx unknown
- 2003-10-03 JP JP2004543148A patent/JP2006504734A/ja active Pending
- 2003-10-10 AR ARP030103707A patent/AR041585A1/es not_active Application Discontinuation
-
2005
- 2005-03-16 NO NO20051389A patent/NO20051389L/no not_active Application Discontinuation
- 2005-04-07 ZA ZA200502842A patent/ZA200502842B/en unknown
- 2005-04-11 EC EC2005005726A patent/ECSP055726A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006504734A (ja) | 2006-02-09 |
RU2005113988A (ru) | 2005-12-10 |
AR041585A1 (es) | 2005-05-18 |
US20040122048A1 (en) | 2004-06-24 |
WO2004032909A2 (en) | 2004-04-22 |
TW200410692A (en) | 2004-07-01 |
CA2500375A1 (en) | 2004-04-22 |
NZ539254A (en) | 2006-03-31 |
KR20050049541A (ko) | 2005-05-25 |
EP1549297A2 (en) | 2005-07-06 |
CN1703204A (zh) | 2005-11-30 |
NO20051389L (no) | 2005-06-23 |
BR0314612A (pt) | 2005-07-26 |
MXPA05003671A (es) | 2005-06-08 |
WO2004032909A3 (en) | 2004-07-01 |
ZA200502842B (en) | 2007-11-28 |
AU2003279803A1 (en) | 2004-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055726A (es) | Composición farmacéutica estabilizada que contiene excipientes básicos | |
CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
CY1108843T1 (el) | 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων | |
DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
AR038527A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
ECSP055528A (es) | Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco | |
CY1113462T1 (el) | Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο | |
CO5590918A2 (es) | Formulaciones | |
EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
NO20091955L (no) | Antivirale sammensetninger, og fremgangsmater for anvendelse | |
PA8599701A1 (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr | |
HRP20070291T3 (en) | Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis | |
ECSP045397A (es) | 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS | |
DK1150704T3 (da) | Melagatran til behandling af betændelse | |
NO20073023L (no) | Forhindring av vertikal endoparasitt infeksjoner | |
ECSP045405A (es) | Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa | |
NO20074167L (no) | Peptidiske forbindelser | |
SE0200657D0 (sv) | Novel Formulation | |
TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
EA200501565A1 (ru) | Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса | |
ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
DK1603584T3 (da) | Aplidine til behandling af multipelt myelom | |
BRPI0507985A (pt) | derivados de piperazina uréia para o tratamento de endometriose |